Biovitrum Expands Kineret® License to Include Certain Orphan
Indications
(Thomson Reuters ONE) - Stockholm, Sweden November 27, 2009 - Biovitrum AB (publ) (STO:BVT)today announced an agreement with Amgen to expand Biovitrum's Kineretlicense to include certain orphan indications. The amendedlicense provides Biovitrum exclusive rights to develop, manufacture,market and sell Kineret for these additional orphan indications. InDecember 2008, Biovitrum obtained from Amgen the global exclusiverights to Kineret for rheumatoid arthritis as currently indicated onits label."We are pleased that we now have the opportunity to further developthe innovative drug Kineret for rare serious diseases and make itavailable to additional patients with high unmet medical needs," saidMartin Nicklasson, CEO of Biovitrum. Furthermore, we will be able tofurther leverage Kineret product value and the agreement validatesour good and longstanding relationship with Amgen," Nicklasson added.About Kineret® (anakinra)Information about Kineret® can be found at the following site:http://www.kineretrx.com/Healthcare professionals should refer to and rely upon the PDR(Physician's Desk Reference) or the corresponding national labelingtexts.About BiovitrumBiovitrum is an international pharmaceutical company that marketsspecialist pharmaceuticals in several regions. Using its expertiseand experience Biovitrum takes scientific innovation to patients withsignificant unmet medical need. Research expertise and capabilitiesare focused on development and production of biotechnologytherapeutics within our prioritized areas of hemophilia,inflammation/autoimmune diseases, cancer supportive care andmalabsorption. The company has revenues of approximately SEK 1.2billion and around 400 employees. The company head office is locatedin Sweden and it is listed on the Stockholm OMX Nordic Exchange. Formore information please visit www.biovitrum.com.For further information, please contactBiovitrum AB (publ)Erik Kinnman, EVP Investor RelationsPhone: +46 73 422 15 40erik.kinnman(at)biovitrum.comMartin Nicklasson, CEOPhone. +46 8 697 2327Biovitrum AB (publ) may be required to disclose the informationprovided herein pursuant to the Swedish Securities Markets Act. Theinformation was provided for public release on November 27, 2009 at8.30 a.m. CET.http://hugin.info/134557/R/1357584/330300.pdfThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 27.11.2009 - 08:31 Uhr
Sprache: Deutsch
News-ID 8930
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 271 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Biovitrum Expands Kineret® License to Include Certain Orphan
Indications"
steht unter der journalistisch-redaktionellen Verantwortung von
Biovitrum (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
